Compare GSK plc (GSK) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Target Corporation — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Target Corporation trades at $141.03 (market cap $62.81B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TGT | |
|---|---|---|
Market Cap | $101.34B | $62.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $141.19 |
52-Week Low | $36.20 | $83.68 |
Enterprise Value | $121.95B | $78.11B |
Dividend Yield | 3.49% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Target (TGT) trades at $140.69, up 5.02% today, with strong technical momentum indicated by bullish moving averages. Recent earnings beats and a 3.24% net income margin highlight operational resilience, while a P/E of 18.27 and P/S of 0.59 suggest reasonable valuation. Positive news flow notes improving traffic trends from merchandising initiatives, supporting near-term optimism.
The outlook remains balanced with potential upside from execution on merchandising resets and consistent dividend payments, but risks include competitive pressures and margin volatility. Analyst consensus is mixed with a $137 price target slightly below current levels, indicating cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
